反向淋巴绘图用于乳腺癌相关淋巴水肿的微血管淋巴结移植供区安全性:一项前瞻性研究
该前瞻性研究基于Lymfactin® I期和II期试验数据,纳入51例乳腺癌相关淋巴水肿女性,评估腹股沟微血管淋巴结移植伴或不伴乳房再造的供区安全性。术后1年双下肢体积差变化22.6 ml(范围-813至860.2 ml,p=0.067),无患者12个月随访时下肢体积差超过10%。结论认为反向淋巴绘图下腹股沟微血管淋巴结移植看似安全,术后一年内不增加继发性供区淋巴水肿风险。
要点
- 51例乳腺癌相关淋巴水肿女性接受腹股沟微血管淋巴结移植,其中25例单纯移植、26例联合乳房再造。
- 术后1年双下肢体积差变化22.6 ml(范围-813至860.2 ml,p=0.067),无患者12个月时体积差超过10%。
- 最常见不良事件为术后疼痛(17.7%)、伤口愈合问题(11.8%)和血清肿形成(11.8%),64.6%为轻度。
核心结论
- 这项前瞻性研究显示,采用反向淋巴绘图的腹股沟微血管淋巴结移植看似安全,术后一年内不增加继发性供区淋巴水肿风险。
研究设计与样本
- 数据来自Lymfactin® I期和II期试验(2016至2019年),采用围手术期反向淋巴绘图,纳入51例乳腺癌相关淋巴水肿女性,平均年龄55.5岁,平均病程31.8个月。
- 25例(49%)接受微血管淋巴结移植(VLNT组),26例(51%)接受微血管淋巴结移植联合乳房再造(VLNT-BR组);两组年龄(p=0.766)、BMI(p=0.316)和乳腺癌相关淋巴水肿病程(p=0.994)相似。
- 术前及术后3、6、12个月测量下肢体积,研究访视期间记录不良事件。
主要发现
- 一年期间双下肢体积差变化22.6 ml(范围-813至860.2 ml)(p=0.067)。
- 12个月随访时无患者下肢体积差超过10%。
- 最常见不良事件为术后疼痛(17.7%)、伤口愈合问题(11.8%)和血清肿形成(11.8%);大多数不良事件(64.6%)分类为轻度。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vascularized lymph node transfer (VLNT) is one option among other surgical treatments in the management of breast cancer-related lymphedema (BCRL). The cause of concern regarding VLNT harvested from the groin has been the potential development of secondary lower-extremity lymphedema. This study explored the risks associated with donor-site morbidity following groin VLNT, with or without concomitant breast reconstruction. METHOD: The cohort comprised data from the Lymfactin® Phase I and II trials, conducted from 2016 to 2019, that used perioperative reverse lymphatic mapping. The volume of the lower extremities was measured preoperatively and at 3, 6, and 12 months postoperative, and the adverse events were documented during study visits. RESULTS: Altogether, 51 women with a mean age of 55.5 years were recruited. The mean duration of BCRL was 31.8 months. Among these, 25 (49%) underwent VLNT (VLNT-group) and 26 (51%) underwent VLNT in combination with breast reconstruction (VLNT-BR group). The groups were similar in terms of age, (p = 0.766), BMI (p = 0.316), and duration of BCRL (p = 0.994). Across a period of one year, the volume difference between the lower extremities changed by 22.6 ml (range: -813 to 860.2 ml) (p = 0.067). None of the patients had lower-extremity volume difference exceeding 10% at the 12-month follow-up visit. The most frequent adverse events were postoperative pain (17.7%), wound healing issues (11.8%), and seroma formation (11.8%). Most adverse events (64.6%) were classified as minor. CONCLUSIONS: This prospective study demonstrated that groin VLNT with reverse lymphatic mapping appears safe and does not increase the risk of secondary donor-site lymphedema within one year postoperatively.
引用
- Pajula S, Saarikko A, Suominen S, et al. Donor-site safety in microvascular lymph node transfer for breast cancer-related lymphedema using reverse lymphatic mapping-A prospective study. J Plast Reconstr Aesthet Surg. 2024. PMID: 39226714. doi:10.1016/j.bjps.2024.08.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。